Advertisement

Molecular Medicine

, Volume 18, Issue 6, pp 1009–1017 | Cite as

Liver X Receptor Regulates Rheumatoid Arthritis Fibroblast-like Synoviocyte Invasiveness, Matrix Metalloproteinase 2 Activation, Interleukin-6 and CXCL10

  • Teresina Laragione
  • Pércio S Gulko
Research Article

Abstract

Fibroblast-like synoviocyte (FLS) invasiveness correlates with articular damage in rheumatoid arthritis (RA), yet little is known about its regulation. In this study we aimed to determine the role of the nuclear receptor liver X receptor (LXR) in FLS invasion. FLS were isolated from synovial tissues obtained from RA patients and from DA rats with pristane-induced arthritis. Invasion was tested on Matrigel-coated chambers in the presence of the LXR agonist T0901317, or control vehicle. FLS were cultured in the presence or absence of T0901317, and supernatants were used to quantify matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, interleukin-6 (IL-6), tumor necrosis factor-α and C-X-C motif chemokine ligand 10 (CXCL10). Nuclear factor-κB (NF-κB) (p65) and Akt activation, actin cytoskeleton, cell morphology and lamellipodia formation were also determined. The LXR agonist T0901317 significantly reduced DA FLS invasion by 99% (P ≤ 0.001), and RA FLS invasion by 96% (P ≤ 0.001), compared with control. T0901317-induced suppression of invasion was associated with reduced production of activated MMP-2, IL-6 and CXCL10 by RA FLS, and with reduction of actin filament reorganization and reduced polarized formation of lamellipodia. T0901317 also prevented both IL-1β-induced and IL-6-induced FLS invasion. NF-κB (p65) and Akt activation were not significantly affected by T0901317. This is the first description of a role for LXR in the regulation of FLS invasion and in processes and pathways implicated both in invasion as well as in inflammatory responses. These findings provide a new rationale for considering LXR agonists as therapeutic agents aimed at reducing both inflammation and FLS-mediated invasion and destruction in RA.

Notes

Acknowledgments

The authors thank M Keogh and C Mason of the Feinstein Institute’s Tissue Donation Program for their assistance in obtaining RA synovial tissues. Funding was provided by the National Institutes of Health grants R01-AR46213, R01-AR052439 (NIAMS) and R01-AI54348 (NIAID) to P Gulko.

Supplementary material

10020_2012_1861009_MOESM1_ESM.pdf (418 kb)
Liver X Receptor Regulates Rheumatoid Arthritis Fibroblast-like Synoviocyte Invasiveness, Matrix Metalloproteinase 2 Activation, Interleukin-6 and CXCL10

References

  1. 1.
    Gossec L, et al. (2004) Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann. Rheum. Dis. 63:675–80.CrossRefGoogle Scholar
  2. 2.
    Wolfe F, et al. (1994) The mortality of rheumatoid arthritis. Arthritis Rheum. 37:481–94.CrossRefGoogle Scholar
  3. 3.
    Muller-Ladner U, et al. (1996) Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol. 149:1607–15.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Bartok B, Firestein GS. (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233:233–55.CrossRefGoogle Scholar
  5. 5.
    Laragione T, Brenner M, Mello A, Symons M, Gulko PS. (2008) The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts. Arthritis Rheum. 58:2296–306.CrossRefGoogle Scholar
  6. 6.
    Tolboom TC, et al. (2005) Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis Rheum. 52:1999–2002.CrossRefGoogle Scholar
  7. 7.
    van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. (1993) Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol. 20:1288–96.PubMedGoogle Scholar
  8. 8.
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 44:2009–17.CrossRefGoogle Scholar
  9. 9.
    Drossaers-Bakker KW, et al. (1999) Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42:1854–60.CrossRefGoogle Scholar
  10. 10.
    Brenner M, Linge CP, Li W, Gulko PS. (2011) Increased synovial expression of nuclear receptors correlates with protection in pristane-induced arthritis: a possible novel genetically regulated homeostatic mechanism. Arthritis Rheum. 63:2918–29.CrossRefGoogle Scholar
  11. 11.
    Wang K, Wan YJ. (2008) Nuclear receptors and inflammatory diseases. Exp. Biol. Med. (Maywood). 233:496–506.CrossRefGoogle Scholar
  12. 12.
    Nuclear Receptors Nomenclature Committee. (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell. 97:161–3.CrossRefGoogle Scholar
  13. 13.
    Brenner M, et al. (2012) Identification of two new arthritis severity loci that regulate levels of autoantibodies, IL-1beta and joint damage. Arthritis Rheum. 64;1369–78.CrossRefGoogle Scholar
  14. 14.
    Birrell MA, et al. (2007) Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J. Biol. Chem. 282:31882–90.CrossRefGoogle Scholar
  15. 15.
    Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9:213–9.CrossRefGoogle Scholar
  16. 16.
    Cui G, et al. (2011) Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J. Clin. Invest. 121:658–70.CrossRefGoogle Scholar
  17. 17.
    A-Gonzalez N, et al. (2009) Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 31:245–58.CrossRefGoogle Scholar
  18. 18.
    Chintalacharuvu SR, Sandusky GE, Burris TP, Burmer GC, Nagpal S. (2007) Liver X receptor is a therapeutic target in collagen-induced arthritis. Arthritis Rheum. 56:1365–7.CrossRefGoogle Scholar
  19. 19.
    Park MC, Kwon YJ, Chung SJ, Park YB, Lee SK. (2010) Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Rheumatology. 49:882–90.CrossRefGoogle Scholar
  20. 20.
    Vingsbo C, et al. (1996) Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am. J. Pathol. 149:1675–83.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Arnett FC, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315–24.CrossRefGoogle Scholar
  22. 22.
    Laragione T, Gulko PS. (2010) mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol. Med. 16:352–8.CrossRefGoogle Scholar
  23. 23.
    Schultz JR, et al. (2000) Role of LXRs in control of lipogenesis. Genes Dev. 14:2831–8.CrossRefGoogle Scholar
  24. 24.
    Tolboom TC, et al. (2002) Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann. Rheum. Dis. 61:975–80.CrossRefGoogle Scholar
  25. 25.
    Livak KJ, Schmittgen TD. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–8.CrossRefGoogle Scholar
  26. 26.
    Sasaki M, et al. (2000) Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1beta and TNF-alpha. Mediators Inflamm. 9:155–60.CrossRefGoogle Scholar
  27. 27.
    Laragione T, Brenner M, Sherry B, Gulko PS. (2011) CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum. 63:3274–83.CrossRefGoogle Scholar
  28. 28.
    Verderame M, Alcorta D, Egnor M, Smith K, Pollack R. (1980) Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells. Proc. Natl. Acad. Sci. U. S. A. 77:6624–8.CrossRefGoogle Scholar
  29. 29.
    Brenner M, Laragione T, Mello A, Gulko PS. (2007) Cia25 on rat chromosome 12 regulates severity of autoimmune arthritis induced with pristane and with collagen. Ann. Rheum. Dis. 66:952–7.CrossRefGoogle Scholar
  30. 30.
    Jenkins E, Brenner M, Laragione T, Gulko PS. (2012) Synovial expression of Th17-related and cancer-associated genes is regulated by the arthritis severity locus Cia10. Genes Immun. 13:221–3.CrossRefGoogle Scholar
  31. 31.
    Laragione T, Brenner M, Li W, Gulko PS. (2008) Cia5d regulates a new fibroblast-like synoviocyte invasion-associated gene expression signature. Arthritis Res. Ther. 10:R92.CrossRefGoogle Scholar
  32. 32.
    Goldbach-Mansky R, et al. (2000) Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Res. 2:145–53.CrossRefGoogle Scholar
  33. 33.
    Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B. (2001) Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum. 44:2263–74.CrossRefGoogle Scholar
  34. 34.
    Machesky LM. (2008) Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 582:2102–11.CrossRefGoogle Scholar
  35. 35.
    Tilghman RW, et al. (2005) Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J. Cell. Sci. 118:2613–23.CrossRefGoogle Scholar
  36. 36.
    Jiang Y, et al. (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43:1001–9.CrossRefGoogle Scholar
  37. 37.
    Neidhart M, Gay RE, Gay S. (2000) Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 43:1719–28.CrossRefGoogle Scholar
  38. 38.
    Joosten LA, et al. (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163:5049–55.PubMedGoogle Scholar
  39. 39.
    Nishimoto N, et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66:1162–7.CrossRefGoogle Scholar
  40. 40.
    Sasai M, et al. (1999) Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42:1635–43.CrossRefGoogle Scholar
  41. 41.
    Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y. (1992) Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum. 35:1197–201.CrossRefGoogle Scholar
  42. 42.
    Kirkham BW, et al. (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 54:1122–31.CrossRefGoogle Scholar
  43. 43.
    Walter M, Liang S, Ghosh S, Hornsby PJ, Li R. (2009) Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene. 28:2745–55.CrossRefGoogle Scholar
  44. 44.
    Hanaoka R, et al. (2003) A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res. Ther. 5: R74–81.CrossRefGoogle Scholar
  45. 45.
    Kuan WP, et al. (2010) CXCL 9 and CXCL 10 as Sensitive markers of disease activity in patients with rheumatoid arthritis. J. Rheumatol. 37:257–64.CrossRefGoogle Scholar
  46. 46.
    Yellin M, et al. (2009) A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 60(Suppl 10):414.Google Scholar
  47. 47.
    Salomon I, et al. (2002) Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 169:2685–93.CrossRefGoogle Scholar
  48. 48.
    Cheng O, Ostrowski RP, Liu W, Zhang JH. (2010) Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaB. Neuroscience. 166:1101–9.CrossRefGoogle Scholar
  49. 49.
    Pommier AJ, et al. (2010) Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene. 29:2712–23.CrossRefGoogle Scholar
  50. 50.
    Asquith DL, et al. (2009) Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum. 60:2655–65.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Laboratory of Experimental Rheumatology, Center for Genomics and Human GeneticsFeinstein Institute for Medical ResearchManhassetUSA
  2. 2.Elmezzi Graduate School of Molecular MedicineManhassetUSA

Personalised recommendations